Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
Alternative lengthening of telomeres
H3.3
Paediatric high-grade gliomas
Telomeres
pHGG
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
04
2020
accepted:
16
10
2020
pubmed:
1
11
2020
medline:
29
6
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
The maintenance of telomere length prevents cancer cell senescence and occurs via two mutually exclusive mechanisms: (a) reactivation of telomerase expression and (b) activation of alternative lengthening of telomeres (ALT). ALT is frequently related to alterations on ATRX, a chromatin-remodelling protein. Recent data have identified different molecular subgroups of paediatric high-grade glioma (pHGG) with mutations of H3F3A, TERTp and ATRX; however, differences in telomere length among these molecular subgroups were not thoroughly examined. We investigated which genetic alterations trigger the ALT mechanism in 52 IDH-wildtype, 1p/19q-wildtype pHGG. Samples were analysed for telomere length using Tel-FISH. ATRX nuclear loss of expression was assessed by IHC, H3F3A and TERTp mutations by DNA sequencing, and TERTp methylation by MS-PCR. Mutant H3.3 was found in 21 cases (40.3%): 19.2% with K27M mutation and 21.1% with G34R mutation. All H3.3G34R-mutated cases showed the ALT phenotype (100%); on the opposite, only 40% of the H3.3K27M-mutated showed ALT activation. ATRX nuclear loss was seen in 16 cases (30.7%), associated sometimes with the G34R mutation, and never with the K27M mutation. ATRX nuclear loss was always related to telomere elongation. TERTp C250T mutations were rare (5.4%) and were not associated with high intensity Tel-FISH signals, as TERTp hyper-methylation detected in 21% of the cases. H3.3/ATRX/TERTp-wildtype pHGG revealed all basal levels of telomere length. Our results show a strong association between H3.3 mutations and ALT, and highlight the different telomeric profiles in histone-defined subgroups: H3.3-G34R mutants always trigger ALT to maintain telomere length, irrespective of ATRX status, whereas only some H3.3-K27M tumours activate ALT. These findings suggest that acquiring the gly34 mutation on H3.3 might suffice to trigger the ALT mechanism.
Identifiants
pubmed: 33128602
doi: 10.1007/s00381-020-04933-8
pii: 10.1007/s00381-020-04933-8
pmc: PMC7875853
doi:
Substances chimiques
X-linked Nuclear Protein
EC 3.6.4.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-818Références
Akincilar SC, Unal B, Tergaonkar V (2016) Reactivation of telomerase in cancer. Cell Mol Life Sci 73:1659–1670
doi: 10.1007/s00018-016-2146-9
Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q et al (2017) Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49:349–357
doi: 10.1038/ng.3781
Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ (2018) ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. PLoS One 13(9):e0204159. https://doi.org/10.1371/journal.pone.0204159
doi: 10.1371/journal.pone.0204159
pubmed: 30226859
pmcid: 6143253
Castelo-Branco P, Sanaa C, Mack S et al (2013) Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 14:534–542. https://doi.org/10.1016/S1470-2045(13)70110-4
doi: 10.1016/S1470-2045(13)70110-4
pubmed: 23598174
Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028.
doi: 10.1016/j.cell.2015.12.028.
pubmed: 26824661
pmcid: 26824661
Cesare AJ, Griffith JD (2004) Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol 24(22):9948–9957. https://doi.org/10.1128/MCB.24.22.9948-9957.2004
doi: 10.1128/MCB.24.22.9948-9957.2004
pubmed: 15509797
pmcid: 525488
Chiba K, Lorbeer FK, Shain AH et al (2017) Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science 357(6358):1416–1420. https://doi.org/10.1126/science.aao0535
doi: 10.1126/science.aao0535
pubmed: 28818973
pmcid: 5942222
Cohen AL, Holmen SL, Colman H (2013) IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13(5):345. https://doi.org/10.1007/s11910-013-0345-4
doi: 10.1007/s11910-013-0345-4
pubmed: 23532369
pmcid: 4109985
Danussi C, Promita B, Prosanna T et al (2018) Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nat Commun 9:1057. https://doi.org/10.1038/s41467-018-03476-6
doi: 10.1038/s41467-018-03476-6
pubmed: 29535300
pmcid: 5849741
Dilley RL (2015) & Greenberg, R.A (2015). ALTernative telomere maintenance and cancer. Trends Cancer 1(2):145–156. https://doi.org/10.1016/j.trecan.2015.07.007
doi: 10.1016/j.trecan.2015.07.007
pubmed: 26645051
pmcid: 4669901
Diplas A, He X, Brosnan-Cashman JA et al (2018) The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun 9(1):2087. https://doi.org/10.1038/s41467-018-04448-6
doi: 10.1038/s41467-018-04448-6
pubmed: 5970234
pmcid: 5970234
Dorris K, Sobo M, Onar-Thomas A et al (2014) Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. J Neuro-Oncol 117(1):67–76. https://doi.org/10.1007/s11060-014-1374-9
doi: 10.1007/s11060-014-1374-9
Ebrahimi A, Skardelly M, Bonzheim I et al (2016) ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4:60. https://doi.org/10.1186/s40478-016-0331-6
doi: 10.1186/s40478-016-0331-6
pubmed: 4910252
pmcid: 4910252
Episkopou H, Draskovic I, Van Beneden A et al (2014) Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. Nucleic Acids Res 42:4391–4405. https://doi.org/10.1093/nar/gku114
doi: 10.1093/nar/gku114
pubmed: 24500201
pmcid: 3985679
Fan H-C, Chen C-M, Chi C-S et al (2019) Targeting telomerase and ATRX/DAXX inducing tumor senescence and apoptosis in the malignant glioma. Int J Mol Sci 20(1):200. https://doi.org/10.3390/ijms20010200
doi: 10.3390/ijms20010200
pubmed: 6337644
pmcid: 6337644
Flynn RL, Cox KE, Jeitany M, Wakimoto H et al (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 33:221–235. https://doi.org/10.1126/science.1257216
doi: 10.1126/science.1257216
Gauchier M, Kan S, Barral A, Sauzet S et al (2019) SETDB1-dependent heterochromatin stimulates alternative lengthening of telomeres. Sci Adv 5:eaav3673. https://doi.org/10.1126/sciadv.aav3673
doi: 10.1126/sciadv.aav3673
pubmed: 31086817
pmcid: 6506250
Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T (2013) H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. Am J Clin Pathol 139:345–349. https://doi.org/10.1309/AJCPABOHBC33FVMO
doi: 10.1309/AJCPABOHBC33FVMO
pubmed: 23429371
Heaphy CM, De Wilde RF, Jiao Y et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333(6041):425. https://doi.org/10.1126/science.1207313
doi: 10.1126/science.1207313
pubmed: 21719641
pmcid: 3174141
Heaphy CM, Subhawong AP, Hong SM et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615. https://doi.org/10.1016/j.ajpath.2011.06.018
doi: 10.1016/j.ajpath.2011.06.018
pubmed: 21888887
pmcid: 3181356
Hemann MT, Strong MA, Hao LY, Greider CW (2001) The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107:67–77
doi: 10.1016/S0092-8674(01)00504-9
Henson JD, Cao Y, Huschtscha LI, Chang AC, Au AY, Pickett HA et al (2009) DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 27:1181–1185. https://doi.org/10.1038/nbt.1587
doi: 10.1038/nbt.1587
pubmed: 19935656
Huang DS, Wang Z, He XJ, Diplas BH et al (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumor types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51(8):969–976. https://doi.org/10.1016/j.ejca.2015.03.010
doi: 10.1016/j.ejca.2015.03.010
pubmed: 25843513
pmcid: 4467782
Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14:651–661
doi: 10.1038/nrc3811
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021–6026. https://doi.org/10.1073/pnas.1303607110.
doi: 10.1073/pnas.1303607110.
pubmed: 23530248
pmcid: 3625331
Koelsche C, Sahm F, Capper D, Reuss D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–914. https://doi.org/10.1007/s00401-013-1195-5
doi: 10.1007/s00401-013-1195-5
pubmed: 24154961
Lai TP, Wright WE, Shay JW (2018) Comparison of telomere length measurement methods. Philos Trans R Soc Lond Ser B Biol Sci 373(1741). https://doi.org/10.1098/rstb.2016.0451
Lang M, Jegou T, Chung I, Richter K, Münch S, Udvarhelyi A et al (2010) Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 123:392–400. https://doi.org/10.1242/jcs.053496
doi: 10.1242/jcs.053496
pubmed: 20130140
Lee J, Solomon DA, Tihan T (2017) The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neuro-Oncol 132(1):1–11. https://doi.org/10.1007/s11060-016-2349-9
doi: 10.1007/s11060-016-2349-9
Lee DD, Leão R, Komosa M, Gallo M et al (2019) DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest 129(1):223–229. https://doi.org/10.1172/JCI121303
doi: 10.1172/JCI121303
pubmed: 30358567
Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD (2010) Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 107(32):14075–14080. https://doi.org/10.1073/pnas.1008850107
doi: 10.1073/pnas.1008850107
pubmed: 20651253
pmcid: 2922592
Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4
doi: 10.1007/s00401-007-0243-4
pubmed: 17618441
pmcid: 1929165
Lovejoy CA, Li W, Reisenweber S, Thongthip S et al (2012) Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8(7):e1002772. https://doi.org/10.1371/journal.pgen.1002772
doi: 10.1371/journal.pgen.1002772
pubmed: 22829774
pmcid: 3400581
Lu R, O’rourke JJ, Sobinoff AP et al (2019) The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT). Nat Commun 10:2252. https://doi.org/10.1038/s41467-019-10180-6
doi: 10.1038/s41467-019-10180-6
pubmed: 31138797
pmcid: 6538672
Mackay A, Burford A, Carvalho D et al (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32(4):520–537.e5. https://doi.org/10.1016/j.ccell.2017.08.017
doi: 10.1016/j.ccell.2017.08.017
pubmed: 28966033
pmcid: 28966033
Mangerel J, Price A, Castelo-Branco P et al (2014) Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol 128:853–862. https://doi.org/10.1007/s00401-014-1348-1
doi: 10.1007/s00401-014-1348-1
pubmed: 25315281
Minasi S, Baldi C, Pietsch T et al (2019) Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. J Neuro-Oncol 142:435–444. https://doi.org/10.1007/s11060-019-03127-w
doi: 10.1007/s11060-019-03127-w
Nabetani A, Ishikawa F (2011) Alternative lengthening of telomeres pathway: recombination-mediated telomere maintenance mechanism in human cells. J Biochem 149:5–14. https://doi.org/10.1093/jb/mvq119
doi: 10.1093/jb/mvq119
pubmed: 20937668
Nonoguchi N, Ohta T, Oh JE et al (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937. https://doi.org/10.1007/s00401-013-1163-0
doi: 10.1007/s00401-013-1163-0
pubmed: 23955565
Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522. https://doi.org/10.1016/j.ccr.2010.03.017.
doi: 10.1016/j.ccr.2010.03.017.
pubmed: 20399149
pmcid: 2872684
Oganasian L, Karlseder J (2009) Telomeric armor: the layers of end protection. J Cell Sci 122:4013–4025. https://doi.org/10.1242/jcs.050567
doi: 10.1242/jcs.050567
Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology 17(Suppl 4):iv1–iv62
doi: 10.1093/neuonc/nov189
Pollack IF, Hamilton RL, Sobol RW et al (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv Syst 27(1):87–94. https://doi.org/10.1007/s00381-010-1264-1
doi: 10.1007/s00381-010-1264-1
pubmed: 20725730
Poon SS, Lansdorp PM (2001) Quantitative fluorescence in situ hybridization (Q-FISH). Curr Protoc Cell Biol. Chapter 18, Unit18 14. Wiley. https://doi.org/10.1002/0471143030.cb1804s12
Reifenberger G, Weber RG, Riehmer V et al (2014) Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 135(8):1822–1831. https://doi.org/10.1002/ijc.28836
doi: 10.1002/ijc.28836
pubmed: 24615357
Rodriguez FJ, Brosnan-Cashman JA, Allen SJ et al (2019) Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathol 29(1):126–140. https://doi.org/10.1111/bpa.12646
doi: 10.1111/bpa.12646
pubmed: 30192422
Rubtsova MP, Vasilkova DP, Malyavko AN, Naraikina YV, Zvereva MI, Dontsova OA (2012) Telomere lengthening and other functions of telomerase. Acta Nat 2:44–61
doi: 10.32607/20758251-2012-4-2-44-61
Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231. https://doi.org/10.1038/nature10833
doi: 10.1038/nature10833
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. https://doi.org/10.1016/j.ccr.2012.08.024.
doi: 10.1016/j.ccr.2012.08.024.
pubmed: 23079654
Wang Z, Rice SV, Chang TC, Liu Y, Liu Q, Qin N, Putnam DK, Shelton K, Lanctot JQ, Wilson CL et al (2019) Molecular mechanism of telomere length dynamics and its prognostic value in pediatric cancers. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djz210
(2016) WHO classification of tumours of the central nervous system revised, 4th edn. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) IARC, Lyon
Xu M, Qin J, Wang L et al (2019) Nuclear receptors regulate alternative lengthening of telomeres through a novel noncanonical FANCD2 pathway. Sci Adv 5(10):eaax6366. https://doi.org/10.1126/sciadv.aax6366
doi: 10.1126/sciadv.aax6366
pubmed: 31633027
pmcid: 6785246
Yamamoto H, Iwasaki T, Yamada Y et al (2018) Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol 73:41–50. https://doi.org/10.1016/j.humpath.2017.11.020
doi: 10.1016/j.humpath.2017.11.020
Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59(17):4175–4179
pubmed: 10485449
Yoshimoto K, Hatae R, Sangatsuda Y et al (2017) Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34:103–112. https://doi.org/10.1007/s10014-017-0287-7
doi: 10.1007/s10014-017-0287-7
pubmed: 28447171
Zhang JM, Yadav T, Ouyang J (2019) Alternative lengthening of telomeres through two distinct break-induced replication pathways. Cell Rep 26(4):955–968.e3. https://doi.org/10.1016/j.celrep.2018.12.102
doi: 10.1016/j.celrep.2018.12.102
pubmed: 30673617
pmcid: 6366628
Zhao S, Lin Y, Xu W, Jiang W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324(5924):261–265. https://doi.org/10.1126/science.1170944
doi: 10.1126/science.1170944
pubmed: 19359588
pmcid: 3251015